Structure of the carboxyl terminus of the RAS gene-encoded P21 proteins. 1988

P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
Department of Medicine, Columbia-Presbyterian Medical Center, New York, NY 10032.

The three-dimensional structures of the carboxyl-terminal regions of the P21 protein products of the human Harvey (Ha), Kirsten (KiA and KiB), and neuroblastoma (N) RAS oncogenes and various mutants have been determined by using conformational energy analysis. The carboxyl-terminal region of P21 has been strongly implicated in the binding of the protein to the inner surface of the plasma membrane without which the protein is inactive. The only invariant residue in this region is Cys-186, which is necessary for the post-translational addition of palmitic acid. The surrounding sequences of the active native proteins differ considerably. Nevertheless, certain amino acid substitutions in this region are known to eliminate membrane binding and protein activity, suggesting that there is a conserved common structural feature in this region in the native proteins that is disrupted in the mutant proteins. Conformational energy analysis shows that the four native P21 proteins have a common structure in the form of an alpha-helix for the terminal pentapeptide. A mutant, pBW277, that fails to bind to the membrane and is inactive cannot adopt an alpha-helical structure in this region because of a proline at position 188. Another mutant, pBW766, that retains membrane binding and activity, on the other hand, retains the preference for an alpha-helical conformation in the terminal pentapeptide. These findings suggest that, despite various amino acid sequences in this region, the carboxyl-terminal pentapeptides of the P21 proteins form a distinctive structural domain that must have an alpha-helical structure for membrane binding and intracellular activity.

UI MeSH Term Description Entries
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D016283 Proto-Oncogene Proteins p21(ras) Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47. Proto-Oncogene Proteins c-ras,c-Ha-ras p21,c-Ki-ras p21,p21(N-ras),p21(c-Ha-ras),p21(c-Ki-ras),p21(c-ras),p21(ras),ras Proto-Oncogene Protein p21,Proto-Oncogene Protein p21(c-Ha-ras),Proto-Oncogene Protein p21(c-Ki-ras),Proto-Oncogene Protein p21(c-N-ras),Proto-Oncogene Protein p21(ras),Proto-Oncogene Protein ras,c-ras Proteins,p21 c-H-ras,p21 c-Ha-ras,p21 c-K-ras,p21 c-Ki-ras,p21 c-ras,ras Proto-Oncogene Product p21,Proteins c-ras, Proto-Oncogene,Proto Oncogene Protein ras,Proto Oncogene Proteins c ras,c Ha ras p21,c Ki ras p21,c ras Proteins,c-H-ras, p21,c-Ha-ras, p21,c-K-ras, p21,c-Ki-ras, p21,c-ras, Proto-Oncogene Proteins,c-ras, p21,p21 c H ras,p21 c Ha ras,p21 c K ras,p21 c Ki ras,p21 c ras,p21, c-Ha-ras,p21, c-Ki-ras,ras Proto Oncogene Product p21,ras Proto Oncogene Protein p21,ras, Proto-Oncogene Protein

Related Publications

P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
January 1986, Gene amplification and analysis,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
June 1992, Journal of biomolecular structure & dynamics,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
August 1990, Nihon rinsho. Japanese journal of clinical medicine,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
February 2005, Blood,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
November 1995, Journal of protein chemistry,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
July 1988, The Journal of biological chemistry,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
January 1993, Ciba Foundation symposium,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
January 1996, Journal of protein chemistry,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
January 1992, Annals of clinical and laboratory science,
P W Brandt-Rauf, and R P Carty, and J Chen, and M Avitable, and J Lubowsky, and M R Pincus
January 1995, Methods in enzymology,
Copied contents to your clipboard!